<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MMR-proficient colon cancer &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mmr-proficient-colon-cancer/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 20 Oct 2025 16:17:39 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>MMR-proficient colon cancer &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neoadjuvant Immunotherapy Advances in MMR-Proficient Colon Cancer</title>
		<link>https://bioengineer.org/neoadjuvant-immunotherapy-advances-in-mmr-proficient-colon-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 20 Oct 2025 16:17:14 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Dual checkpoint blockade]]></category>
		<category><![CDATA[Major pathological response]]></category>
		<category><![CDATA[MMR-proficient colon cancer]]></category>
		<category><![CDATA[Neoadjuvant immunotherapy]]></category>
		<category><![CDATA[NICHE clinical trial]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neoadjuvant-immunotherapy-advances-in-mmr-proficient-colon-cancer/</guid>

					<description><![CDATA[In recent years, immune checkpoint blockade (ICB) has revolutionized the treatment landscape for various malignancies, marking a new era in oncology. Therapies targeting immune checkpoints like PD-1 and CTLA-4 have demonstrated remarkable success in cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma. However, a significant challenge persists with colorectal cancer, particularly [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">283863</post-id>	</item>
	</channel>
</rss>
